[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts– July 14, 2023– ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN) (“ProMIS” or the “Corporation”) is delighted to reveal that it has actually finished its continuation (the “Continuance”) from the Canada Business Corporations Act into the Province of Ontario under the Business Corporations Act (Ontario) since July 13, 2023. The Continuance was authorized by the Corporation’s investors with a 97.7% bulk through an unique resolution at the Corporation’s Annual Meeting of Shareholders hung on June 29, 2023. The shift will assist in internal management functions, and is not imagined to affect operations. The Company continues to run with its head office in Toronto along with its lab, under the instructions of Chief Scientific Officer Dr. Neil Cashman, in British Columbia and its United States workplace in Cambridge, MA. No action will be needed by existing investors with regard to the Continuance. Neither the TSX nor Nasdaq has actually evaluated and neither accepts obligation for the adequacy or precision of this release. About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is an advancement phase biotechnology corporation concentrated on finding and establishing antibody rehabs selectively targeting poisonous oligomers linked in the advancement and development of neurodegenerative illness, in specific Alzheimer’s illness (ADVERTISEMENT), amyotrophic lateral sclerosis (ALS) and Multiple system atrophy (MSA). The Corporation’s exclusive target discovery engine is based upon making use of 2 complementary strategies. The Corporation uses its thermodynamic, computational discovery platform – ProMIS and Collective Coordinates – to anticipate unique targets called Disease Specific Epitopes on the molecular surface area of misfolded proteins. Utilizing this special technique, the Corporation is establishing unique antibody therapies for advertisement, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, Canada with workplaces in Cambridge, Massachusetts, U.S.A. ProMIS is noted on the TSX under sign PMN, and on the NASDAQ under the sign PMN. Positive Statements Neither the TSX nor Nasdaq has actually evaluated and neither accepts obligation for the adequacy or precision of this release. Specific details in this press release makes up positive declarations and positive details (jointly,”positive details”) within the significance of appropriate securities laws. Sometimes, however not always in all cases, positive info can be determined by the usage of positive terms such as “strategies”, “targets”, “anticipates” or “does not anticipate”, “is anticipated”, “a chance exists”,”is po
Learn more
